{"id":"NCT01342965","sponsor":"Hoffmann-La Roche","briefTitle":"A Study of Erlotinib (Tarceva) Versus Gemcitabine/Cisplatin as First-line Treatment in Patients With Non-small Cell Lung Cancer With EGFR Mutations","officialTitle":"A Multicenter, Open-label, Randomized Phase III Study to Evaluate the Efficacy and Safety of Erlotinib (TarcevaÂ®) Versus Gemcitabine/Cisplatin as the First-line Treatment for Stage IIIB/IV Non-small Cell Lung Cancer (NSCLC) Patients With Mutations in the Tyrosine Kinase Domain of Epidermal Growth Factor Receptor (EGFR) in Their Tumors","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2011-03","primaryCompletion":"2012-07","completion":"2014-04","firstPosted":"2011-04-27","resultsPosted":"2015-02-24","lastUpdate":"2015-02-24"},"enrollment":217,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Non-Small Cell Lung Cancer"],"interventions":[{"type":"DRUG","name":"Erlotinib","otherNames":["Tarceva"]},{"type":"DRUG","name":"Chemotherapy","otherNames":[]}],"arms":[{"label":"Erlotinib","type":"EXPERIMENTAL"},{"label":"Chemotherapy","type":"ACTIVE_COMPARATOR"}],"summary":"This open-label, randomized, parallel arm study assessed the efficacy and safety of Tarceva (erlotinib) versus gemcitabine/cisplatin combination chemotherapy as first-line treatment in patients with stage IIIB/IV non-small cell lung cancer with epidermal growth factor receptor (EGFR) mutations in their tumours. Patients were randomized to receive either Tarceva 150 mg orally daily or 3-week cycles of gemcitabine 1250 mg/m\\^2 intravenously (iv) on Days 1 and 8 plus cisplatin 75 mg/m\\^2 iv on Day 1.","primaryOutcome":{"measure":"Investigator-assessed Duration of Progression-free Survival","timeFrame":"Baseline to the data cut-off date of 20 Jul 2012 (1 year, 4 months)","effectByArm":[{"arm":"Erlotinib","deltaMin":11,"sd":null},{"arm":"Chemotherapy","deltaMin":5.5,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":5,"exclusionCount":9},"locations":{"siteCount":28,"countries":["China","Malaysia","Philippines"]},"refs":{"pmids":["29654023","26105600"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":22,"n":110},"commonTop":["Rash","Nausea","Vomiting","Diarrhoea","Leukopenia"]}}